Tuesday, January 18, 2022 9:24:21 PM
Alzheimer's disease is easier to treat at the earliest stage possible. See the image below to understand why this is true.
The above is especially true if you are targeting upstream MOA with precision medicine.
The Anavex Blarcamesine Phase 2b/3 trial is for early stage Alzheimer's disease with baseline MMSE scores of 20 to 28 inclusive
Prevention of Alzheimer's disease via Blarcamesine or Anavex 3-71 would be the earliest stage possible.
Good luck and GOD bless
Recent AVXL News
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
